Connect with us
European Gaming Congress 2024

Artificial Intelligence

Atrin Pharmaceuticals Adds Critical Genomics Capabilities in Advance of Initiating First Clinical Trial Through Ongoing Collaboration with Predictive Technology Group

Published

on

DOYLESTOWN, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) — Atrin Pharmaceuticals, a private biopharmaceutical company pioneering the discovery and development of proprietary molecules targeting DNA Damage and Repair (DDR) pathways to treat cancers that currently do not have effective therapies, today reported preliminary results from a collaborative genomics analysis that will be used to optimize patient selection for Atrin’s upcoming ATRN-119 clinical trial.  This genomics analysis was a result of Atrin’s collaboration with Predictive Technology Group to utilize next-generation genomics capabilities to improve predictive selection of clinical study patients most likely to respond and least likely to experience side effects from treatment with Atrin’s DDR drug candidates. 
Atrin and Predictive have been jointly developing proprietary approaches to better identify patients with specific mutations that drive cancer tumor growth, regardless of tumor type, and who are most likely to clinically respond to synthetically-lethal anti-cancer therapies. Predictive’s genomics capabilities were added to Atrin’s existing proprietary proteomic and medicinal chemistry technologies to improve targeting of DDR proteins that are active in cancer cells and relatively inactive in healthy cells, ahead of Atrin’s initiation of a Phase 1/2a clinical study of ATRN-119, Atrin’s lead oral drug candidate.Predictive is using a genomic data base analytics approach to help with patient selection, to increase efficiencies and quality of clinical trials, and to shorten time to market for Atrin’s drug candidates. Atrin’s pipeline also includes preclinical drug candidates in development for glioblastoma and hematological disorders that are being advanced towards IND enabling studies.Oren Gilad, Ph.D., President and Chief Executive Officer of Atrin Pharmaceuticals, noted: “Our collaboration with Predictive, as shown in this genomics analysis, is already resulting in improved targeting of eligible patients for the upcoming Phase 1/2a ATRN-119 clinical study, and could potentially result in adoption of a new diagnostic for this type of anti-cancer treatment. Predictive’s unique genomic insights and modeling provide Atrin with enhanced diagnostic tools to accelerate Atrin’s DDR therapies and studies.”  Atrin currently expects initiation of the ATRN-119 Phase 1/2a study in 2020, with a first interim clinical readout in 2021.Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, stated: “We are pleased to work with Atrin; their cutting-edge work in discovering and advancing DDR therapies will benefit cancer patients with unmet medical needs. We believe that the Atrin collaboration is a ‘game changer’ that will result in improved design and faster clinical advancement of multiple individualized, precision oncology treatments.  By combining our state-of-the-art proprietary screening assay and related artificial intelligence capabilities with Atrin’s breakthrough DDR therapy candidates, we have the potential to become a leader in development of improved personalized oncology therapies. Both of Predictive’s main entities, Predictive Laboratories and Predictive Analytics, are involved in this ongoing DDR research with Atrin.”Cancer is genomic disease; cancer tumors typically develop when otherwise healthy cells acquire mutations in key “driver genes.” These cancer-causing mutations alter pathways regulating cellular growth and interactions with surrounding tissues.  Understanding the specific gene mutations underlying tumor formation is frequently more important than location of the cancer in selecting personalized anti-cancer therapies.The key to successful cancer therapy is matching specific cancer mutations with efficient and targeted therapies. Multiple benign diseases, cancer-predisposition syndromes, and cancers have now been linked to mutations in DDR genes.  DDR is a clinically validated therapeutic approach, following the commercial approval of multiple blockbuster Poly ADP Ribose Polymerase (PARP) inhibitor products. DDR drugs already represent a multi-billion-dollar market, and it is expected that DDR drugs may ultimately be used to treat over 200 different cancer targets, if a full set of complementary patient-targeting biomarkers are successfully developed and adopted for commercial use.Preliminary results from the collaborative genomics analysis using Predictive’s proprietary assays in patients with a specific tumor type found an excess of DDR mutations in cancer cells compared with normal tissue. The analysis identified 92 genes as protein responders to ATRN-119 treatment, of which 18 genes are known TIER 1 cancer-driver genes, and well-characterized mutations were found in three dominant genes. Both in vitro and animal studies have confirmed synthetically-lethal interactions between ATRN-119 treatment and alteration of these three key cancer-causing genes. The overlap between DDR genes responding to ATRN-119 and those mutated in cancer cells suggest that genetic markers underlying response and resistance will be critical to optimizing patient selection in ATRN-119 clinical studies, by increasing clinical efficacy and minimizing systemic toxicities.Under the terms of the original Atrin-Predictive collaboration agreement, both companies will continue to contribute to the identification of additional druggable targets and pathways, both inside and outside of DDR, to treat a broad group of target indications, particularly in women’s health.About Atrin PharmaceuticalsAtrin Pharmaceuticals, based in Doylestown PA, is a private biotech company focused on discovering and developing proprietary precision cancer therapeutics targeting inhibition of DNA Damage and Repair (DDR) proteins for first-line treatment of cancers. Atrin’s technologies and DDR product pipeline represent a new drug development approach for treating solid and other cancers that currently have limited or ineffective therapies by targeting inhibition of specific proteins that are active in cancer cells and relatively inactive in healthy tissue. For more information, visit www.atrinpharma.com.About Predictive Technology Group, Inc.Predictive Technology Group (OTC PINK: PRED) aims to revolutionize and personalize precision patient care.  The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care.  Predictive’s subsidiaries include Predictive Laboratories, Predictive Analytics, Predictive Biotech and Predictive Therapeutics.  For more information, visit www.predtechgroup.com.Forward-Looking Statements:To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:For more information, visit www.atrinpharma.com www.predtechgroup.com or contact Investor Relations:
For Atrin:
Media ContactMichael King3705 Old Easton RoadDoylestown PA, 18902[email protected]
For Predictive Technology Group:
Media ContactPatrick BurseyLifeSci Public Relations[email protected]646-876-4932Investor ContactJeremy FefferLifeSci Advisors[email protected]212-915-2568

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Sapiens Launches Its Next-Gen Intelligent Insurance Platform

Published

on

sapiens-launches-its-next-gen-intelligent-insurance-platform

Sapiens’ AI-driven platform enables insurers to embrace the latest innovative technologies to make smarter business decisions and increase automation
ROCHELLE PARK, N.J., June 18, 2024 /PRNewswire/ — Sapiens International Corporation, (NASDAQ: SPNS) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, today launched its AI-powered, open, integrated, cloud-native platform. Sapiens Insurance Platform leverages digital engagement, data intelligence, core business processing solutions, and ML and GenAI capabilities to help insurers seamlessly innovate their offerings and processes, enabling them to stay competitive in a dynamic market with smart, data-driven business decisions and hyper automation of business process. The integration of AI across the platform was accelerated by Sapiens’ recent integration with Microsoft, offering insurers advanced GenAI capabilities, as well as tailored and unique solutions to accelerate growth and efficiency. 

Sapiens Insurance Platform speeds growth by supporting end-to-end insurance processes across all lines of business, underscored by Sapiens’ global expertise and local presence around the globe. Moreover, the speed to market Sapiens’ customers gain via the pre-integrated, packaged business solutions ensures rapid deployment and implementation. This allows insurers to swiftly adapt to market changes and offer innovative products and services more efficiently. 
“Sapiens’ next generation enhanced platform empowers our customers to leverage AI across their business processes, enabling them to stay ahead, drive growth, and exceed customer expectations. By adopting the platform approach, streamlining our processes and leveraging shared foundations and technology engines, we deliver even greater value to our customers, more quickly than ever before,” said Roni Al-Dor, Sapiens President & CEO. “Sapiens integration with Microsoft Azure OpenAI accelerates the use of AI services across Sapiens Insurance Platform.”
“Today’s insurers are focused on how to grow their books of business efficiently while making optimal decisions on underwriting, claims and customer service,” said Karlyn Carnahan, head of Celent’s North American insurance practice. “They’re looking for platforms with modern technology to streamline their operations and improve their overall efficiency.  They’re also focused on open APIs for easy integration to broad ecosystems, easy configuration tools to tailor functionality to their specific needs, and above all, access to data. Solutions that offer these kinds of modern capabilities are gaining the most momentum with insurers.” 
Sapiens Insurance Platform provides insurers with a robust ecosystem to streamline operations and enhance customer experiences. Sapiens chose Microsoft Azure as their cloud provider due to its enterprise focus, perfectly suited to the needs of large insurers.  
“Our collaboration with Sapiens highlights Microsoft’s dedication to empowering the insurance industry with transformative AI solutions. This collaboration not only showcases the potential of Microsoft Azure and our AI technologies but also sets a new standard for innovation within the insurance industry,” said Patrice Amann, regional leader, financial services at Microsoft.
About Sapiens  
Sapiens International Corporation (NASDAQ and TASE: SPNS) is a global leader in intelligent insurance software solutions. With Sapiens’ robust platform, customer-driven partnerships, and rich ecosystem, insurers are empowered to future-proof their organizations with operational excellence in a rapidly changing marketplace. We help insurers harness the power of AI and advanced automation to support core solutions for property and casualty, workers’ compensation, and life insurance, including reinsurance, financial & compliance, data & analytics, digital, and decision management. Sapiens boasts a longtime global presence, serving over 600 customers in more than 30 countries with its innovative SaaS offerings. Recognized by industry experts and selected for the Microsoft Top 100 Partner program, Sapiens is committed to partnering with our customers for their entire transformation journey and is continuously innovating to ensure their success.
For more information visit https://sapiens.com or follow us on LinkedIn  
Investor and Media Contact 
Yaffa Cohen-Ifrah Chief Marketing Officer and Head of Investor Relations Sapiens International Email: [email protected]
Forward-Looking Statements 
Certain matters discussed in this press release that are incorporated herein and therein by reference are forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, that are based on our beliefs, assumptions and expectations, as well as information currently available to us. Such forward-looking statements may be identified by the use of the words “anticipate,” “believe,” “estimate,” “expect,” “may,” “will,” “plan” and similar expressions. Such statements reflect our current views with respect to future events and are subject to certain risks and uncertainties. There are important factors that could cause our actual results, levels of activity, performance or achievements to differ materially from the results, levels of activity, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to:  the degree of our success in our plans to leverage our global footprint to grow our sales; the degree of our success in integrating the companies that we have acquired through the implementation of our M&A growth strategy; the lengthy development cycles for our solutions, which may frustrate our ability to realize revenues and/or profits from our potential new solutions; our lengthy and complex sales cycles, which do not always result in the realization of revenues; the degree of our success in retaining our existing customers or competing effectively for greater market share; the global macroeconomic environment, including headwinds caused by inflation, relatively high interest rates, potentially unfavorable currency exchange rate movements, and uncertain economic conditions, and their impact on our revenues, profitability and cash flows; difficulties in successfully planning and managing changes in the size of our operations; the frequency of the long-term, large, complex projects that we perform that involve complex estimates of project costs and profit margins, which sometimes change mid-stream; the challenges and potential liability that heightened privacy laws and regulations pose to our business; occasional disputes with clients, which may adversely impact our results of operations and our reputation; various intellectual property issues related to our business; potential unanticipated product vulnerabilities or cybersecurity breaches of our or our customers’ systems; risks related to the insurance industry in which our clients operate; risks associated with our global sales and operations, such as changes in regulatory requirements, wide-spread viruses and epidemics like the coronavirus epidemic,  and fluctuations in currency exchange rates; and risks related to our principal location in Israel and our status as a Cayman Islands company.
While we believe such forward-looking statements are based on reasonable assumptions, should one or more of the underlying assumptions prove incorrect, or these risks or uncertainties materialize, our actual results may differ materially from those expressed or implied by the forward-looking statements. Please read the risks discussed under the heading “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2023, to be filed in the near future, in order to review conditions that we believe could cause actual results to differ materially from those contemplated by the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, to conform these statements to actual results or to changes in our expectations.
Logo: http://mma.prnewswire.com/media/585787/Sapiens_Logo.jpg 
 

View original content:https://www.prnewswire.co.uk/news-releases/sapiens-launches-its-next-gen-intelligent-insurance-platform-302175460.html

Continue Reading

Artificial Intelligence

LONGi Chief Scientist Dr. Xu Xixiang Wins 2024 IEEE William R. Cherry Award

Published

on

longi-chief-scientist-dr-xu-xixiang-wins-2024-ieee-william-r.-cherry-award

XI’AN, China, June 18, 2024 /PRNewswire/ — The world-leading solar technology company, LONGi Green Energy Technology Co., Ltd. (hereafter as “LONGi”), announced today that its Chief Scientist and Vice President of LONGi Central R&D Institute, Dr. Xu Xixiang, has won the 2024 IEEE William R. Cherry Award at the 52th IEEE PVSC for major breakthroughs in the field of PV industry. Dr. Xu Xixiang has become the first Chinese scientist to be honored with this distinction.

The William R. Cherry Award is named in honor of William R. Cherry, a founder of the photovoltaic community. In the 1950’s, he was instrumental in establishing solar cells as the ideal power source for space satellites and for recognizing, advocating, and nurturing the use of photovoltaic systems for terrestrial applications. The purpose of the award is to recognize an individual engineer or scientist who devoted a part of their professional life to the advancement of the science and technology of photovoltaic energy conversion. 
Dr. Xu Xixiang is currently leading an R&D team over 500 technical staff members working on multiple PV technologies. He led the team and created 14 world records of Si solar cell efficiency and now holds efficiency records of HJT, HBC and PVSK/HJT tandem solar cells, which are 26.81%, 27.3% and 34.6%, respectively.
LONGi is not only the creator of the world record for solar cell efficiency, but also a leader in promoting innovation in the global photovoltaic industry. In recent years, LONGi has collaborated with upstream and downstream partners in the industry chain to innovate multiple industry-leading innovative technologies, including diamond wire cutting technology, monocrystalline PERC technology, HPBC solar cell industrialization, etc., making positive contributions to the cost reduction and efficiency increase of the entire industry, as well as the reduction of photovoltaic electricity costs.
LONGi has always been the company with the most R&D investment in the PV industry. Since its listing in 2012 until the end of 2023, LONGi has accumulated more than 30 billion yuan in R&D investment and has obtained a total of 2,879 authorized patents of various types.
Speaking of receiving this honor, Dr. Xu Xixiang said: “I am deeply honored to have received the William R. Cherry Award. In the past few years, with the joint efforts of our R&D team, we have repeatedly created and broken world records for solar cell efficiency. This award belongs not only to me, but also to every member of the LONGi Central R&D Institute. In the future, we will continue to strive to develop more cutting-edge technologies while accelerating the commercialization of these PV technologies. Our ultimate goal is ‘making the best of solar energy to build a green world’.”
Upon learning of Dr. Xu Xixiang’s award, Li Zhenguo, Founder and President of LONGi, immediately congratulated him and said: “On behalf of LONGi, we’d like to congratulate Dr. Xu Xixiang and his team on this remarkable honor and his outstanding achievements in the field of PV industry. we are grateful for Dr. Xu Xixiang’s contributions and efforts in this regard. In the future, LONGi will adhere to the concept of “seeking development through innovation” and make unremitting efforts to achieve the goal of “zero carbon earth” with more valuable technologies and products.”
On June 14th, 2024 in Shanghai, LONGi was just officially announced a new efficiency record of 34.6% for its developed PVSK tandem solar cells at 2024 SNEC EXPO, breaking the efficiency record of 33.9% created by Dr. Xu Xixiang’s R&D team themselves. The new efficiency record of 34.6% has been certified by the European Solar Test Installation (ESTI).
During the SNEC EXPO, Li Zhenguo, Founder and President of LONGi, was honored as the “Global Solar Leader”, and Dr. Xu Xixiang, Chief Scientist and Vice President of LONGi Central R&D Institute, was also awarded the honor of “Global Solar Scientist”. This selection activity is initiated by the Global Green Energy Council, Global Solar Council, Asia Pacific New Energy Industry Association, and Asia Photovoltaic Industry Association, and is supported and organized by influential industry organizations, authoritative academic institutions, and international media worldwide. The aim is to recognize outstanding leaders and technological innovation pioneers who have made extraordinary contributions to the global photovoltaic industry. The achievements of the winners not only drive industry progress, but also set a new benchmark for the global renewable energy industry.
About LONGi
Founded in 2000, LONGi is committed to being the world’s leading solar technology company, focusing on customer-driven value creation for full scenario energy transformation.
Under its mission of ‘making the best of solar energy to build a green world’, LONGi has dedicated itself to technology innovation and established five business sectors, covering mono silicon wafers cells and modules, commercial & industrial distributed solar solutions, green energy solutions and hydrogen equipment. The company has honed its capabilities to provide green energy and has more recently, also embraced green hydrogen products and solutions to support global zero carbon development. www.longi.com
Photo – https://mma.prnewswire.com/media/2441266/image_5006479_6301869.jpgPhoto – https://mma.prnewswire.com/media/2441267/image_5006479_6301963.jpgLogo – https://mma.prnewswire.com/media/1606520/LONGi_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/longi-chief-scientist-dr-xu-xixiang-wins-2024-ieee-william-r-cherry-award-302175447.html

Continue Reading

Artificial Intelligence

New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers

Published

on

new-study-finds-cybersecurity-as-top-concern-among-automotive-manufacturers

Global survey reveals shifting priorities, increased technology investments, and workforce engagement challenges in the automotive industry
BRUSSELS, June 18, 2024 /PRNewswire/ — Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 9th annual “State of Smart Manufacturing Report: Automotive Edition.” The global study encompasses the responses of 182 leaders from automotive manufacturers, automotive supply manufacturers, and electric vehicle manufacturers across 15 of the leading manufacturing countries.

This year’s report emphasizes the evolution of the automotive industry, revealing a focus on harnessing emergent technology to reduce risk, generate growth, and maximize workforce potential. Automotive manufacturers are acutely aware of the industry’s evolution in the era of Industry 4.0, particularly as cyberattacks resulted in $1.99 billion in system downtime costs in the first half of 2023 alone.
Key global findings include:
Cybersecurity risk is listed as the top external obstacle for automotive manufacturers in 2024 – up from 9th position in 2023.97% of automotive manufacturers are using or evaluating smart manufacturing technology – up from 85% in 2023.Technology investments increased 35% year-over-year, from 23% to 31% of the operating budget.Wearable technology is listed as one of the top 10 investment areas for automotive manufacturers in 2024, ranking third overall.Employee engagement is the top workforce-related obstacle for automotive manufacturers in 2024.Reducing manufacturing waste is the factor that matters most to automotive manufacturers’ ESG programs.”As the automotive industry is navigating an era of rapid transformation, setting clear goals and fostering cross-departmental collaboration have emerged as critical factors—and obstacles—for success,” said James Glasson, vice president, global industry – auto, tire & advanced mobility at Rockwell Automation. “This year’s report highlights the pressing need for automotive manufacturers to prioritize organizational change management and adopt technologies that enhance the capabilities of their workforce.”
Automotive manufacturers are focusing on strategies that prioritize workforce retention, upskilling, and engagement. Technologies such as smart manufacturing and automation, which complement and augment the value brought by their employees, are key to driving positive business outcomes.
“At Rockwell, our deep industry expertise and comprehensive portfolio of industry solutions, combined with our extensive PartnerNetwork™, puts us in a unique position to serve as a trusted advisor to automotive companies worldwide,” said Glasson. “Regardless of where companies are in their digital transformation and smart manufacturing journeys, we meet them where they are and help them achieve sustainable growth.”
The full findings of the report can be found here.
Methodology
This report is based on the responses of 182 managers and executives from automotive manufacturers, automotive supply manufacturers, and electric vehicle manufacturers in 15 countries. It’s part of the 9th annual State of Smart Manufacturing report, which surveyed 1,567 manufacturing leaders across multiple industries and was conducted in association with Sapio Research and Rockwell Automation.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
Logo – https://mma.prnewswire.com/media/1981317/Rockwell_Automation_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/new-study-finds-cybersecurity-as-top-concern-among-automotive-manufacturers-302174103.html

Continue Reading
Advertisement
Stake.com
Advertisement

Latest News

Trending